Moderna and Merck's Melanoma Vaccine Clears Key Hurdle

Moderna and Merck announced that their mRNA melanoma vaccine has met key goals in a Phase 3 trial. This personalized cancer treatment could become available as early as 2027.

The Phase 3 trial for the mRNA melanoma vaccine showed promising results, meeting its primary endpoint of overall survival. The vaccine targets specific genetic mutations in melanoma patients, allowing for a tailored approach to treatment.

While there is no word on a price or availability date yet, Moderna and Merck are expected to file for FDA approval soon.